TREATMENT OF MAST CELL DISEASES AND EOSINOPHILIC DISORDERS
The present disclosure relates to the use of Compound (I) or a pharmaceutically acceptable salt thereof, for the treatment of mast cell diseases and eosinophilic disorders.
1 . A method of treating a mast cell disease, comprising administering to a subject in need thereof a therapeutically effective amount of Compound (I):
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the mast cell disease is selected from mast cell activation syndrome (MCAS), and hereditary alpha tryptasemia (HAT).
3 . The method of claim 2 , wherein the MCAS is selected from primary MCAS (monoclonal mast cell activation syndrome (MMAS)), secondary MCAS (MCAS that arises from another disease), and idiopathic MCAS (MCAS that rules out primary or secondary MCAS).
4 . The method of claim 2 , wherein the mast cell disease is hereditary alpha tryptasemia (HAT)(overexpression of TPSAB1 causing elevated tryptase)).
5 . The method of claim 2 , wherein the mast cell disease is selected from mast cell mediated asthma, anaphylaxis (including idiopathic, Ig-E and non-Ig-E mediated), urticaria (including idiopathic and chronic), atopic dermatitis, swelling (angioedema), irritable bowel syndrome, mastocytic gastroenteritis, mastocytic colitis, pruritus, chronic pruritis, pruritis secondary to chronic kidney failure and heart, vascular, intestinal, brain, kidney, liver, pancreas, muscle, bone and skin conditions associated with mast cells.
6 . The method of claim 1 , wherein the mast cell disease is associated with wild type KIT.
7 . The method of claim 1 , wherein the subject does not have a mutation in Exon 17 KIT.
8 . The method of claim 7 , wherein the subject does not have a D816V mutation in KIT.
9 . A method of treating an eosinophilic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of Compound (I):
or a pharmaceutically acceptable salt thereof.
10 . The method of claim 9 , wherein the eosinophilic disorders is selected from eosinophilic esophagitis, eosinophilic gastroenteritis, eosinophilic fasciitis, and Churg-Strauss syndrome.
11 . The method of claim 1 , wherein the subject has a mutation in Exon 17 in KIT.
12 . The method of claim 11 , wherein the subject has a D816 mutation in KIT in Exon 17.
13 . The method of claim 12 , wherein the D816 mutation is D816V.
14 . The method of claim 12 , wherein the D816 mutation is D816Y.
15 . The method of claim 1 , wherein the therapeutically effective amount is 30-400 mg.
16 . The method of claim 15 , wherein the therapeutically effective amount is 100-300 mg per day.
17 . The method of claim 16 , wherein the therapeutically effective amount is 100 mg per day.
18 . The method of claim 16 , wherein the therapeutically effective amount is 200 mg per day.
19 . The method of claim 16 , wherein the therapeutically effective amount is 300 mg per day.